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1201-83 ete-Adrenergic Inhibition of Leptin Production is 
Attenuated in Obese Individuals 
John M. Dooo. Alexei V. Agapitov, William G. Haynes, Christine A, Sinkey, Vireod K. 
Somers, Bradley G. Phillips, University of Iowa, Iowa Ci~ Iowa. 
Background: Leptin regulates body weight and may affect cardiovascular function. Leptin 
expression from adipocytes is suppressed by beta-receptor stimulation. Obese subjects 
have high leptin levels and are at increased risk for cardiovascular disease, We tested 
the hypothesis that suppression of leptin production from adipocytes following beta- 
receptor stimulation is attenuated in obese subjects. 
Methods: We studied 8 obese (age 35 ± 3 yrs, BMI 35 ± 2 kg/m2) and 8 age and gender 
matched lean controls (age 35 ± 3 yrs, BMI 24 ± 1 kg/m2). All subjects were norrnoten- 
sire, free of disease and were not taking any medications. In a randomized fashion, sub- 
jects received either a 4 hour infusion of normal saline or isoproterenol (to increase 
resting heart rate by 25%) on two separate days. Blood samples for plasma leptin were 
drawn at baseline and at 30 minute intervals during both infusions. 
Results: Leptin levels decreased by 7.8 ± 1.5% at the end of isoproterenol and increased 
by 3.1 ± 4,8% during normal saline in obese subjects (p < 0.05). in controls, leptin 
decreased by 16,8 ± 3.4% and 9.0 ± 4,8% with isoproterenol and normal saline, respec- 
tively (p < 0.05). During isoproterenol, the maximum percent decrease from baseline in 
leptin was 10.3 ± 3.3% in obese subjects and 19.2 ± 2.1% in lean controls (p < 0.02). The 
area under the curve (AUC) for percent change in leptin levels with isoproterenol was 
significantly less in obese subjects compared to lean controls (1799 ± 287 versus 2818 ± 
203, p < 0.05), The infusion rate of isoproterenol in obese subjects was 0.47 ± 0,1 rncg/ 
rain and 0.36 ± 0.06 mcg/min in controls (p = 0.05). 
Conclusion: Isoproterenol significantly decreased plasma leptin levels in both obese and 
tean subjects compared to normal saline. Beta-adrenergic stimulation that induced com- 
parable increases in heart rate in both Jean and obese subjects resulted in a lower level 
of leptin suppression in obese subjects. This blunted suppression of leptin production is 
even evident dudng higher doses of isoproterenol in obese subjects. Thus, there appears 
to be an attenuated beta-adrenergic suppression of leptin production in obese individu- 
als. 
1201-84 Difference of High-Sensitive C-Reactive Protein Levels 
in Patients Treated With Stat lns,  Aspirin, and 
Angiotensln II Modulators 
Toshihiro Takeda. Shire Hoshida, Shinichiro Suna, Masayuki Taniike, Yasuyuki Egami, 
Ryu Shutta, Masayoshi Kawabata, Masami Nishino, Hideo Tanahashi, Jun Tanouchi, 
Yoshio Yamada, Osaka Rosai Hospital, ok. 
Objectives The anti-inflammatory effects of statins, aspirin, and angiotensin II modula- 
tors (A II-M), such as angiotensin-converting enzyme inhibitors and angiotensin II type I 
receptor blockades, were examined by measuring serum high-sensitive C-reective pro- 
tein (hs-CRP) levels in patients with and without ischemic heart disease (IHD). Back- 
ground Statins, aspirin and A II-M may have a clinical anti-inflammatory action. Although 
statins have been shown to reduce CRP levels, the relationship between the effects of 
statins, aspirin and A II-M on CRP levels remains to be determined. Methods We exam- 
ined serum hs-CRP levels in consecutive patients who were scheduled for coronary 
angiography with (n=979, 65± 1 years, male/female 731/248) and without (n=200, 64±1 
years, male/female 102/98) IHD. The blood was withdrawn on the day of catheterization. 
Hyperlipidemia (HL) was defined as total cholesterol >220 and/or triglycerides >150 rag/ 
dl. Results In IHD patients, hs-CRP levels were significantly higher than in non-IHD 
patients (0.34±0.02 vs 0.26±0.03 mg/dl, p<0.05), although no difference in hs-CRP lev- 
els was observed between patients with and without HL in each group. The low levels of 
hs-CRP in the non-IHD patients were not reduced by the treatment with statins, but the 
high levels of hs-CRP in the IHD patients were significantly reduced by the treatment with 
statins (0.27±0.02 mg/dl, p<0.05). In all patients included, neither aspirin nor A II-M had 
any effect on hs-CRP levels in both groups. Interestingly, however, in the patients not 
treated with statins, A II-M, but not aspirin, significantly reduced hs-CRP levels only in 
IHD patients (A II-M, 0.41±0.04 vs 0.32±0.03 mg/dl, p<0.05; aspirin, 0.34±0.03 vs 
0.38¢0.03 mg/dl, ns). Conclusions Statins have an anti-inflammatory action assessed 
by measurement of CRP levels in IHD, but not in non-IHD, patients. A II-M also have an 
anti-inflammatory action only in IHD patients, but the effect is smaller than that of statins 
in terms of CRP levels. 
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1202-85 Fol ic Acid Supplementation Substantially Reduces 
Hyperhomocysteinemia Induced by Fenoflbrate 
Voitec h Melenovskv, Tomas Btulc, Barbora Grauova, Dan Wichterle, Viktor Kozich, 
Jakub Krijt, Tomas Haas, Richard Ceska, 3rd Department of Medicine, Genera/ 
University Hospital, Prague, Czech Republic, Institute of Inherited Metabolic 
Diseases, 1st Medical Facul~ Prague, Czech Republic. 
BACKGROUND: Plasma homocysteine (Hcy) is an independent risk factor of atheroscle- 
rosis. An increase of Hcy levels during treatment with fibrates has been reported. This 
phenomenon may explain lower efficacy of fibrates on mortality. The effect of Folic acid 
(FA) on fibrate-induced Hcy elevation has never been studied. 
METHODS: 37 subjects (15 wo, 50±10y) with hypedipidemia were randomized to 8 
weeks of treatment with micronised fenofibrate (F) 200rag/day or F 200 rag/day + Folic 
acid 5 mg/day (F+FA). Subjects with vitamin B use or deficiency, diabetes, renal or thy- 
roid disease were excluded. Blood lipids, creatinine (Creat), plasma FA, cysteine (Cys) 
and Hcy (by HPLC) were determined before and after treatments. The between-group 
differences were tested by ANCOVA. 
RESULTS: Serum Hcy increased after F by 52.5% (from 11.5 ± 3.0 to 17 ± 6.5 pmol/I), 
after F+FA only by 12.5% (from 10.4 ± 1.9 to 11.7± 2.5 ~mol/I), (p = 0.001). Cys 
increased after F by 14% (from 321 ± 32 to 366 ± 53 IJmol/I) and after F+FA by 16,6% 
(from 292 ± 34 to 340 ± 30 pmol/I), (NS). Craat increased after F by 20% (from 90 ± 12 to 
108 ± 14 pmol/I), after F+FA by 9% (from 90 ± 10 to 98 ± 10 pmol/I), (p = 0.015). Plasma 
folate was unchanged after F, after F+FA increased by 152% (from 5.7 ± 1.7 to 14.4 ± 3.9 
mg/I). Groups did not differ in lipid levels. 
CONCLUSIONS: Fenofibrate-inducad Hcy elevation can be effectively reduced by Folic 
acid co-administretion. Folic acid can enhance therapeutic efficacy of fibrates. 
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1202-86 Secretory Phospholipase Is Related to Other Coronary 
Heart Disease Risk Factors 
Sara Mobaspori. Christine C. Tangney, Liping Lu, Robert S. Rosenson, Rush Heart 
Institute, Chicago, Illinois, Northwestern University Medical School, Chicago, Illinois. 
Background: Secretory Phospholipase (sPLA2) remodels LDL and HDL particles, and 
may contribute to vascular inflammatory. This cross-sectional analysis evaluated the 
relations between sPLA 2 and certain CHD risk factors, 
Methods: Plasma lipoprotsin subclasses and particle sizes were measured by nuclear 
magnetic resonance (NMR) spectroscopy (LipoMed, Raleigh, NC). Enzyme immunoas- 
says were used to determine sPLA 2 (Cayman Chemical, Ann Arbor, Ml) and high-sensi- 
tivity C-reactive protein or hs-CRP (Wampole, Cranbury, N J). Pearson correlations were 
done between Iog-transformod sPLA 2 levels and hs-CRP, fipoproteins, age, gender, 
race, BMI (body mass index), hypertension, diabetes, and use of tobacco or hormones. 
Patients were divided into two groups: high sPLA 2 levels (Kugiyama st al., Circulation 
1999;100:1280) and low sPLA 2 levels. Mann Whitney U tests and multiple logistic 
regression analyses was performed between the two groups. 
Results: Ninety-six subjects (40 female, 56 male) with average age of 49 years. The 
means ± SD (medians) of biochemical variables include TG, 254 ± 363 (162) mg/dL; TC, 
229 ± 58 mg/dL; HDL-C, 40±14 mg/dL; LDL-C, 150 ± 53 rng/dL; sPLA2, 176.6 ± 200 
(125.8) pg/mL; hs-CRP, 3.65 ± 6.72 (1.61) mg/dL Log-transformed sPLA2 levels were 
correlated with hs-CRP (r=.60, p<0.00005), HDL size (r=.22, p=0.044), age (r=.26, 
p=0.0f2) and BMI (r=.23, p=0.033). Significantly higher hs-CRP (p=0.00005), larger HDL 
particles, greater BMI (p=0.003), more diabetes, but lower TG (p=0.02) were found in 
subjects with higher sPLA2 (_> 246pg/mL) levels as compared to those with lower levels. 
Conclusion: sPLA 2 levels is a novel inflammatory marker that is elevated in diabetics 
and associated with certain other CHD risk factors characteristic of the metabolic syn- 
drome. 
1202-87 Predictors of 13-Year Changes in the Total Cholesterol 
to High-Density Lipoprotein Cholesterol Ratio 
Richard E. Scranton. Howard D. Sesso, Robert J. Glynn, J. M. Gaziano, Massachusetts 
Veterans Affairs Epidemiology, Research, and Information Center, Boston, 
Massachusetts. 
Background: Many clinical and lifestyle factors modify the total cholesterol to HDL (TC/ 
HDL) ratio, yet few studies have determined what predicts changes in this ratio over time. 
We examined the predictors of the 13-year change in TC/HDL ratio among 4,543 men 
free of coronary artery disease from the Physicians' Health Study who provided baseline 
and follow-up blood samples. 
Methods: Baseline coronary risk factors were included in multivariate linear regression 
models to determine significant predictors of a change in the TC/HDL ratio. The final 
model had an r 2 of .38. 
Results: These men had a mean age of 48.7 + 7 years with a mean total and HDL cho- 
lesterol in 1982 of 214 + 36 mg/dL and 42 _+15 mg/dL, respectively. After a mean follow 
up of 13 years, average total cholesterol decreased by 8 mg/dL, HDL increased by 1 mgJ 
dL and the ratio decreased by 0.38. The parameter estimates and P values for the 
change in TC/HDL ratio are as follows: baseline TC/HDL ratio (-0.49, p<0.0001), age in 
years (-0.03, p<O.0001), systolic blood pressure per mmHg (+0.01, p<0.002), alcohol 
consumption of 1-6 drinkshNeek (-0.16, p=0.02), alcohol consumption of -> 1 ddnks/day (- 
0.25, p=0.004), body mass index > 25 kg/m 2 (+0.27, p<0.0001), hypertension treatment 
(-0.34, p=0 .0002), and hyperlipidemia treatment (-0.65, p<0. 0001). Smoking history, 
exercise, and diabetes were not significant but were included in the model. The exclusion 
of 92 individuals with an MI during the study period did not appreciably change the 
parameter estimates. 
Conclusions: These data suggest that the greatest reductions in the TC/HDL ratio were 
among men receiving pharmacological treatment for hypertension or hypedipidemia. 13- 
